BioTech ABOS

Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers

July 15, 2025 — 07:54 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Acumen Pharmaceuticals (ABOS) announced a collaboration, option and license agreement with JCR Pharmaceuticals to develop an oligomer-targeted Enhanced Brain Delivery therapy for Alzheimers disease. JCR is a global specialty pharmaceuticals company.

Acumen is currently investigating sabirnetug, its lead program, in ALTITUDE-AD, a Phase 2, multi-center, randomized, double-blind, placebo-controlled trial. The company plans to share topline results, including efficacy and safety data, in late 2026. Acumen said the combination of sabirnetug or additional, AO-selective antibodies with JCRs BBB-penetrating technology or J-Brain Cargo strengthens its portfolio of AO-targeted therapies.

JCR will receive an upfront payment and will be eligible for an additional option payment should Acumen exercise its exclusive option to develop up to two development candidates. JCR will also be eligible to receive future development, commercialization and sales milestone payments, as well as single digit percentage royalties on sales of any products that result from the collaboration.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned
ABOS

Latest Articles
Data is currently not available